David Siegel, MD, PhD

Clinical Professor of Medicine
New York University Medical Center
New York, New York
Division Chief, Myeloma
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey

Dr. David Siegel received his medical degree from New York University School of Medicine and his doctorate from New York University Graduate School of Arts and Sciences, Sackler Institute of Basic Medical Sciences, New York City. He continued his postdoctoral training with an internship and residency in internal medicine at New York University/Bellevue Medical Center, and a fellowship in hematology/oncology at Memorial Sloan-Kettering Cancer Center. Dr. Siegel is currently clinical professor of medicine at New York University Medical Center. In addition, he is division chief for myeloma at John Theurer Cancer Center, Hackensack University Medical Center.

Dr. Siegel is board certified in internal medicine and oncology and board eligible in hematology. He is a member of several scientific and medical societies including the American Medical Association, American College of Physicians, American Academy of Cancer Research, American Society of Bone Marrow Transplantation, American Society of Hematology, American Society of Clinical Oncology, and the Southwest Oncology Group.

Dr. Siegel's research is focused on multiple myeloma and he has been published in many leading medical journals, including the British Journal of Haematology, the New England Journal of Medicine, Blood, and Bone Marrow Transplant.

Faculty Disclosure
Dr. David Siegel has received honoraria related to speakers’ bureau activities from Celgene Corporation, Onyx Pharmaceuticals, and Millennium: The Takeda Oncology Company. He has received grant support related to research activities from Millennium.

Dr. Siegel indicated that his material would not include the discussion of unlabeled uses of commercial products or investigational/unapproved products not yet approved by the FDA for any use in the United States.
Last modified: March 23, 2021